With artificial intelligence (AI) and technology, the relationship between tumour changes and tumour assessment endpoints (ORR, PFS etc.) can be modelled to enhance understanding of the drug mechanism of action in clinical oncology studies.
TORONTO (PRWEB)
October 12, 2022
The failure rate of late-stage oncology clinical trials is one of the highest across therapeutic areas, whereas many promising early-stage studies may be prematurely abandoned due to presumably false negative results.
With artificial intelligence (AI) and technology, the relationship between tumour changes and tumour assessment endpoints (ORR, PFS etc.) can be modelled to enhance understanding of the drug mechanism of action in clinical oncology studies.
Join this webinar to meet IAG’s expert team and discuss the latest technological innovations and advanced imaging to support success of oncology clinical trials through quantitative insights.
Join experts from Image Analysis Group, Professor Sotirios Bisdas, MD, PhD, MSc; and Dr. Anitha Singareddy, MD, for the live webinar on Friday, October 21, 2022, at 1pm EDT (10am PDT).
For more information, or to register for this event, visit Response Prediction in Oncology Clinical Trials.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: